OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Pulmonary embolism is a sudden blockage in a lung artery. Blockage usually is caused by a blood clot that travels to the lung from a vein in the leg. Because pulmonary embolism almost always occurs in conjunction with deep vein thrombosis, most doctors refer to the two conditions together as venous thromboembolism. Pulmonary embolism can be life-threatening, but prompt treatment can greatly reduce the risk of death. Stroke was reported in one study and occurred more often in the thrombolytics group than in the control group, although the confidence interval was wide (OR 12.10, 95% CI 1.57 to 93.39).
In United Kingdom, statistical analysis on pulmonary embolism resulted as the most of the studies carried a high risk of bias because of high or unclear risk relating to randomisation and blinding.Meta-analysis showed that, compared with heparin alone, or heparin plus placebo, thrombolytics plus heparin can reduce the odds of death (odds ratio (OR) 0.57, 95% confidence interval (CI) 0.37 to 0.87, P = 0.02, low quality evidence) and recurrence of PE (OR 0.51; 95% CI 0.29 to 0.89, P = 0.02, low quality evidence).